REG - Trellus Health PLC - Appointment of Chief Financial Officer

Trellus HealthAnnouncement

21/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220121:nRSU1606Za&default-theme=true

RNS Number : 1606Z  Trellus Health PLC  21 January 2022

 

Trellus Health plc

("Trellus Health" or the "Company")

 

Appointment of Chief Financial Officer

 

LONDON, UK. AND NEW YORK, U.S. (21 January 2022). Trellus Health plc (AIM:
TRLS), which is commercialising a scientifically validated, resilience-based,
connected health solution for chronic condition management, announces the
appointment of Richard Evans as Interim Chief Financial Officer, with
immediate effect.

 

Richard will replace Salim Hamir who has been fulfilling the role on a
part-time basis and who will continue in the role of Company Secretary.

 

Richard was previously Chief Operating Officer and Finance Director at AIM
listed EKF Diagnostics Holdings plc ("EKF"). Richard has spent more than 11
years at EKF, first as Finance Director and then as Chief Operating Officer,
before taking on both roles. During that time EKF has grown considerably,
delivering record turnover and profits for the year ended 2020, and a series
of performance upgrades during 2021.  Having stood down from the EKF Board on
1 January 2022, Richard will continue to provide handover support to his
successor at EKF, and now has capacity to guide Trellus during a pivotal
period in its development. As the Company develops commercially, it expects to
recruit a permanent CFO later this year.

 

Richard joined EKF in 2011 from Hitachi Data Systems GmbH where he has worked
since 2002, firstly as Finance Director, where he had overall responsibility
for the finance function in Germany, then General Manager and finally as
Global Account Director.

 

Before joining Hitachi Richard held senior positions with various corporations
across Europe. Richard was previously Vice-President Controller Europe for
Fisher Scientific Worldwide, Finance Director of TRW Seat Belt Systems Europe,
and held various roles with the Maxtor Corporation, United Technologies
Carrier and Abbott Diagnostic Products GmbH in Germany.

 

Richard qualified as a Chartered Management Accountant in 1983 and holds a
degree from Edinburgh University and a Masters in Business Administration from
INSEAD.

 

Monique Fayad, CEO of Trellus Health, said: "We are very pleased to welcome
Richard Evans to the Trellus Health team and we look forward to benefitting
from his AIM market experience as well as his extensive knowledge of
operational matters for growing healthcare companies. We are also very
grateful for the valued contribution from Salim Hamir, particularly in the
build up to and during our AIM IPO in May last year, and we appreciate his
continued support as Company Secretary."

 

 

For further information please contact:

 

 Trellus Health plc                                       www.trellushealth.com (http://www.trellushealth.com)
 Monique Fayad, CEO                                       Via Walbrook PR
 Julian Baines, Chairman

 Singer Capital Markets (Nominated Adviser & Broker)      Tel: 020 7496 3000
 Aubrey Powell / Jen Boorer

 Walbrook PR Limited                                      Tel: 020 7933 8780 or trellus@walbrookpr.com (mailto:trellus@walbrookpr.com)
 Paul McManus / Sam Allen                                 Mob: 07980 541 893 / 07502 558 258

 

About Trellus Health plc (www.trellushealth.com (http://www.trellushealth.com)
)

Trellus Health (LSE: TRLS) is a leading pioneer in resilience-driven care and
the first digital health company focused on the intersection of chronic
physical conditions and mental health. Trellus Health's digital-first chronic
care management solution integrates convenient access to a licensed
multidisciplinary care team with a suite of tools for resilience assessment,
education and behavior modification, remote monitoring, health maintenance and
prevention. Through its TrellusElevate™ connected care platform and
companion App, the company enables coordination and delivery of expert
whole-person care, addressing both clinical and behavioral health together, in
context, to improve outcomes and reduce healthcare costs for patients,
employers, and the healthcare system.

 

Trellus Health is commercialising the provision of digital chronic condition
management solutions for employers and health plans that utilise the
scientifically validated resilience-based methodology and a proprietary
HIPAA-compliant technology platform called TrellusElevate™ to coordinate and
deliver personalised care remotely via telehealth. The Company is initially
focused on Inflammatory bowel disease ("IBD"), which includes the chronic
incurable conditions of Crohn's Disease and ulcerative colitis, but considers
its approach to have potential utility and demand across many chronic
conditions.  A direct-to-consumer (DTC) offering is also being devised for
IBD, allowing patients to pay directly or submit claims for insurance
reimbursement utilising existing procedural codes.

 

The TrellusElevate™ platform is the Company's proprietary connected health
platform that incorporates the proprietary methodology and learnings on
resilience from clinical research and practice conducted at the Mount Sinai
IBD Center for more than five years. The proprietary methodology and
resilience-driven multidisciplinary care model have been scientifically
validated to demonstrate meaningful improvements in patient outcomes, 71%
reduction in Emergency Department (A&E) visits, and 94% reduction in
unplanned hospitalisations, which the directors of the Company believe
indicates the potential for significant cost savings for healthcare payers.
IBD patients treated using the methodology also experienced a 49% reduction in
required opioid use and a 73% reduction in corticosteroid use 12 months
following program completion.

 

The Company was founded by Dr. Marla C. Dubinsky, MD and Dr. Laurie Keefer,
PhD, both with decades of combined experience in IBD and
psychogastroenterology, respectively. Trellus Health's patent-pending
GRITT(TM )resilience assessment and personalized treatment methodology was
developed and validated at the Mount Sinai Health System to build resilience
and wellness for improved outcomes at lower cost.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under
the ticker TRLS.  For more information on Trellus Health,
visit www.trellushealth.com (https://trellushealth.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABIGDBUSDDGDG